Clinical Trials
249 trialsA Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Jazz Pharmaceuticals
Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
Sun Yat-sen University
A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）
Sinocelltech Ltd.
CURB-TKI
University Health Network, Toronto
FLINN
Washington University School of Medicine
SELECTmeso
University of Southampton
Sintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLC
Sun Yat-sen University
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.
Shanghai Allink Biotherapeutics Co., Ltd.
REVIVE
University of Chicago
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Boehringer Ingelheim
AmiNA
Janssen Research & Development, LLC
Testing the SurVaxM Vaccine for Lung Cancer Prevention
National Cancer Institute (NCI)
NSCLC， YAP
Guangdong Association of Clinical Trials
ALA /NSCLC
Ain Shams University
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy
Guangdong Provincial People's Hospital
SPRINT 2
Montefiore Medical Center
MIGRANT
Fundación GECP
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
Sichuan University
Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC
Peking University Cancer Hospital & Institute
ALPINE 2
Technische Universität Dresden
BEACON-Lung
Sichuan Cancer Hospital and Research Institute
A Multicenter, Randomized, Cohort, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy
Henan Cancer Hospital
A Phase II Study of GC101 in NSCLC
Shanghai Juncell Therapeutics
Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC
Shanghai Chest Hospital
GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer
Genfleet Therapeutics (Shanghai) Inc.
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC
Dana-Farber Cancer Institute
Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2)
Tianjin Medical University Cancer Institute and Hospital
Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
T-BRAIN
Maastricht University Medical Center
Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC
Shanghai Pulmonary Hospital, Shanghai, China
Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
ORIGIN2
Swiss Cancer Institute
CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer
Roswell Park Cancer Institute
Aurora004
Shanghai Pulmonary Hospital, Shanghai, China
Aurora 005
Shanghai Pulmonary Hospital, Shanghai, China
STAR-01
Sichuan University
Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial
Shanghai Pulmonary Hospital, Shanghai, China
JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
Shanghai Junshi Bioscience Co., Ltd.
Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma
Fudan University
Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC
Hunan Province Tumor Hospital
INSTAR
Yonsei University
Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Phase II)
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
DEFLECT I
University Medical Center Groningen
TianjinCIH
Tianjin Medical University Cancer Institute and Hospital
Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients
Shanghai Pulmonary Hospital, Shanghai, China
GAPIMET
University of Zurich
Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer
Roswell Park Cancer Institute